At a scientific event organized by the National Institute of Health (INS) On the occasion of its 127th institutional anniversary, the latest advances in research and development of dengue vaccines in America and Asia were presented. The seminar was attended by various experts, including specialists from the Pan American Health Organization PAHO/WHOthe Butantan Institute of Brazil and the INS Health Technology Assessment Center.
Challenges in the development of the dengue vaccine
The advances that are being developed in the field of vaccines against dengue are aimed at achieving an effective vaccine against the disease. However, tough challenges are faced, including the importance of conducting clinical trials in Asia and the Americas due to the apparent results of the disease, which has delayed progress in vaccine development.
One of the biggest challenges to be faced is the fact that there are no reliable animal models that can fully mimic the clinical manifestations of the disease, making it difficult to assess the efficacy of candidate vaccines. Therefore, the protective capacity of any vaccine candidate will ultimately be defined by its ability to protect humans from febrile illness.
According to Yamila Romel, PAHO international consultant, having a vaccine will not be a solution to the problem, but an important tool to tip the balance towards disease prevention.
Characteristics of the ideal vaccine against dengue
Within the context of the research that is carried out in the field of vaccines against dengue, it seeks to establish the characteristics of the ideal vaccine against this disease. This would have to be a vaccine that can be used by different age groups, prevent and severe infection, regardless of serotype or genotype. Also, grant protection, regardless of immunity.
Advances in the research and development of dengue vaccines
From the Butantan Institute of Brazil, the medical director in clinical development, José Moreira, said that for a decade work has been done on a preventive vaccine against the four forms of dengue, work carried out in collaboration with the North American National Institute of Health (NIH) of United States, having managed to patent, produce and manufacture this drug, which is applied in clinical trials being carried out at the Butantan Institute.
For his part, the INS epidemiologist adviser, César Cabezas, specified that a whole study and research work is currently being carried out and PAHO plays an important role in this context, and that the determining factors that must be ensured before incorporating these vaccines to public health are costs and quality.
2023-08-04 19:45:59
#INS #advances #research #dengue #vaccines
